The Effect of Hydroxyurea on Vasculopathy in a Child with Sickle Cell Disease

References

1. ↵
   Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996;17:965–972

   Abstract
2. ↵
   Wang W, Langston J, Steen RG, et al. Abnormalities of the central nervous system in very young children with sickle cell anemia. J Pediatrics 1998;132:994–998

   CrossRefPubMedWeb of Science
3. ↵
   Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288–294

   Abstract/FREE Full Text
4. ↵
   Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology 1988;38:1012–1017

   Abstract/FREE Full Text
5. ↵
   Steen RG, Helton KJ, Horwitz EM, et al. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 2001;49:222–229

   CrossRefPubMedWeb of Science
6. ↵
   Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021–1030

   CrossRefPubMedWeb of Science
7. ↵
   Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022–3026

   Abstract/FREE Full Text
8. ↵
   Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS Study, a phase I/II trial. Blood 1999;94:1550–1554

   Abstract/FREE Full Text
9. ↵
   de Montalembert M, Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood 2001;98:2878–2879

   FREE Full Text
10. ↵
    Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyurea in sickle cell disease. Blood 1994;83:1124–1128

    Abstract/FREE Full Text
11. ↵
    Selby R, Nisbet-Brown E, Basran RK, Chang L, Olivieri NF. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 1997;90:891–893

    FREE Full Text
12. ↵
    Russell MO, Goldberg HI, Reis L, et al. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. J Pediatr 1976;88:382–387

    CrossRefPubMedWeb of Science
13. ↵
    Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984;63:162–169

    Abstract/FREE Full Text
14. ↵
    Haacke EM, Lin W. Flow phenomena in magnetic resonance imaging: basic concepts and technical developments. Neuroimaging Clin N Am 1992;2:623–637
15. ↵
    Gillams AR, McMahon L, Weinberg G, Carter AP. MRA of the intracranial circulation in asymptomatic patients with sickle cell disease. Pediatr Radiol 1998;28:283–287

    CrossRefPubMed
16. ↵
    Bridges KR, Barabino GD, Brugnara C, et al. A multi-parameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996;88:4701–4710

    Abstract/FREE Full Text
17. ↵
    Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317–1322

    CrossRefPubMedWeb of Science
18. ↵
    Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 1997;89:1078–1088

    Abstract/FREE Full Text